trelstar has been researched along with Anaphylaxis* in 4 studies
1 review(s) available for trelstar and Anaphylaxis
| Article | Year |
|---|---|
A patient developing anaphylaxis and sensitivity to two different GnRH analogues and a review of literature.
Gonadotropin-releasing hormone analogues are used in the treatment of prostate cancer, breast cancer, endometriosis, and uterine leiomyomas in adults and often in the treatment of precocious puberty in children. Many adverse effects have been reported for gonadotropin-releasing hormone analogues, but anaphylaxis is rarely reported as an adverse effect. Frequent cross-reactions, particularly during childhood, and diversity of the time of onset of anaphylactic manifestations complicate the diagnosis. A patient who exhibited anaphylactic allergic reactions to two different agents used in the treatment of central precocious puberty presented here because the case has an atypical course and is the first in the literature. Topics: Adult; Anaphylaxis; Antineoplastic Agents, Hormonal; Child; Female; Humans; Leuprolide; Prognosis; Puberty, Precocious; Triptorelin Pamoate | 2015 |
1 trial(s) available for trelstar and Anaphylaxis
| Article | Year |
|---|---|
Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone-releasing hormone agonist--a preliminary report.
Recurrent idiopathic anaphylaxis is an illness consisting of recurring anaphylactic or anaphylactoid attacks of unknown cause. A patient has been described whose attacks appeared to be associated with endogenous progesterone secretion and who was treated successfully with an analog of luteinizing hormone-releasing hormone (LHRH). This report summarizes the treatment of four additional women with recurrent anaphylaxis in a randomized, double-blind trial of an LHRH agonist and placebo. Two out of the four women experienced remission of their symptoms with the LHRH analog. The patients who responded to therapy had experienced systemic anaphylactoid reactions after provocation with an LHRH infusion and the intradermal injection of medroxyprogesterone; the nonresponders had no adverse reactions to either challenge. Ovarian suppression with LHRH agonist may benefit a subset of women with recurrent idiopathic anaphylaxis. Topics: Adult; Anaphylaxis; Clinical Trials as Topic; Double-Blind Method; Female; Gonadotropin-Releasing Hormone; Humans; Menstruation; Ovary; Placebos; Random Allocation; Recurrence; Triptorelin Pamoate | 1987 |
2 other study(ies) available for trelstar and Anaphylaxis
| Article | Year |
|---|---|
Use of the cutaneous anaphylactoid test to detect differences in mast cell mediator-releasing activity among LHRH peptides.
The cutaneous anaphylactoid test was evaluated as a screen for assessing mast cell mediator-releasing (MCMR) activity of luteinizing hormone-releasing hormone (LHRH) peptides. As expected, LHRH and D-Trp6-LHRH, an agonist of LHRH, were nonreactive at concentrations of antagonist which induced pronounced skin lesions. Differences between LHRH and antagonists were obvious, but it was difficult to detect differences among antagonists using arithmetic means. However, when the geometric means of the highest positive dilution were calculated, the MCMR activities of the antagonists differed and these differences appeared to be related to the hydrophobicities of their N-termini. Thus, it appears that the cutaneous anaphylactoid test is an appropriate screen to assess the MCMR activity of LHRH peptides and should assist in the development of clinically useful inhibitory analogs of LHRH. Topics: Anaphylaxis; Animals; Female; Gonadotropin-Releasing Hormone; Histamine Release; Mast Cells; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Triptorelin Pamoate | 1987 |
Progesterone sensitivity as a cause of recurrent anaphylaxis.
Topics: Adult; Anaphylaxis; Bronchodilator Agents; Castration; Female; Gonadotropin-Releasing Hormone; Histamine H1 Antagonists; Humans; Lactation; Pregnancy; Progesterone; Recurrence; Triptorelin Pamoate | 1984 |